Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study

Trial Profile

Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs AZD-1775 (Primary) ; Darolutamide (Primary) ; Savolitinib (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms PC-BETS
  • Most Recent Events

    • 04 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top